SCHEDULE: Nomura Holdings Discloses 5.4% Stake in Charles River Labs

Nomura Holdings Inc. has disclosed a passive 5.4% beneficial ownership stake in Charles River Laboratories International, Inc., totaling 2,681,669 shares.

Summary

• Nomura Holdings Inc. reported beneficial ownership of 2,681,669 shares of Charles River Laboratories International, Inc. common stock.
• This represents a 5.4% stake in the company, calculated based on 49,209,000 shares outstanding as of June 28, 2025.
• The ownership includes 473,087 shares and 1,100,000 shares underlying call options held by Nomura Global Financial Products, Inc. (NGFP), a wholly-owned subsidiary.
• It also includes 1,096,182 shares and 12,400 shares underlying call options held by Nomura Securities International, Inc. (NSI), another wholly-owned subsidiary.
• The filing certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Charles River Laboratories International, Inc.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a major financial institution like Nomura Holdings Inc. is generally viewed as a neutral to positive signal, indicating institutional confidence in the issuer without implying activist intent.

Positives

• A major global financial institution, Nomura Holdings Inc., has taken a significant passive stake, potentially signaling institutional confidence in Charles River Laboratories International, Inc.

Negatives

• No specific negative information was disclosed in this filing.

Risks

• The beneficial ownership is stated to be for investment purposes in the ordinary course of business, not for changing or influencing control of the issuer, which means Nomura Holdings Inc. is not expected to pursue activist strategies.

Future Outlook

The filing indicates that Nomura Holdings Inc. holds the shares for investment purposes in the ordinary course of business and does not intend to change or influence the control of Charles River Laboratories International, Inc.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing reflects a standard investment activity by a major global financial institution, Nomura Holdings Inc., in a life sciences company, Charles River Laboratories International, Inc. Such passive stakes are common for institutional investors seeking exposure to specific sectors.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: May view the institutional investment as a vote of confidence, potentially stabilizing or positively influencing share price.
• Management: No direct impact on control or operations, as the stake is passive.

Next Steps

• Continued passive investment in Charles River Laboratories International, Inc. by Nomura Holdings Inc.

Key Dates

Recommendation

The filing indicates a significant passive investment by a reputable financial institution, Nomura Holdings Inc., in Charles River Laboratories International, Inc. This suggests institutional confidence in the company's long-term prospects without any immediate implications for corporate control or strategic shifts. For a seasoned investor, this reinforces a 'hold' position, as it validates the company's attractiveness to large institutional capital, but does not present new fundamental information warranting a 'buy' or 'sell' action based solely on this disclosure.

Keywords

Charles River Laboratories, Nomura Holdings, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment, Life Sciences